The estimated Net Worth of Kenneth Hallock is at least 5.55 百万$ dollars as of 21 January 2022. Kenneth Hallock owns over 300 units of Greenwich LifeSciences stock worth over 5,546,364$ and over the last 4 years Kenneth sold GLSI stock worth over 0$.
Sign up
Kenneth Hallock GLSI stock SEC Form 4 insiders trading
Kenneth has made over 2 trades of the Greenwich LifeSciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Kenneth bought 300 units of GLSI stock worth 4,896$ on 21 January 2022.
The largest trade Kenneth's ever made was buying 74,782 units of Greenwich LifeSciences stock on 29 September 2020 worth over 429,997$. On average, Kenneth trades about 25,027 units every 160 days since 2020. As of 21 January 2022 Kenneth still owns at least 397,304 units of Greenwich LifeSciences stock.
You can see the complete history of Kenneth Hallock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kenneth Hallock's mailing address?
Kenneth's mailing address filed with the SEC is C/O GREENWICH LIFESCIENCES, INC., 3992 BLUEBONNET DR., BUILDING 14, STAFFORD, TX, 77477.
Insiders trading at Greenwich LifeSciences
Over the last 4 years, insiders at Greenwich LifeSciences have traded over 0$ worth of Greenwich LifeSciences stock and bought 654,896 units worth 6,960,565$ . The most active insiders traders include Snehal Patel、Kinnary Patel、Kenneth Hallock. On average, Greenwich LifeSciences executives and independent directors trade stock every 16 days with the average trade being worth of 124,412$. The most recent stock trade was executed by Snehal Patel on 6 August 2024, trading 2,000 units of GLSI stock currently worth 27,620$.
What does Greenwich LifeSciences do?
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
What does Greenwich LifeSciences's logo look like?
Complete history of Kenneth Hallock stock trades at Greenwich LifeSciences
Greenwich LifeSciences executives and stock owners
Greenwich LifeSciences executives and other stock owners filed with the SEC include:
-
Snehal S. Patel,
CEO, CFO & Director -
Snehal S. Patel,
CEO, CFO & Director -
Eric Rothe,
Founder & Independent Director -
Dr. Christine T. Fischette Ph.D.,
VP of Bus. Devel. -
Dr. Jaye L. Thompson Ph.D.,
VP of Clinical & Regulatory Affairs -
Dr. Frank Joseph Daugherty M.D.,
Chief Medical Officer & Director -
Dr. Frank Joseph Daugherty,
Chief Medical Officer & Director -
Snehal Patel,
CEO and CFO -
Kenneth Hallock,
Director -
David Mc Williams,
Director -
Frank Joseph Daugherty,
Chief Medical Officer -
Kinnary Patel,
10% owner -
Jaye Thompson,
VP Clinical Reg Affairs -
Eric Rothe,
Director